Bicara Therapeutics (BCAX) vs Nanobiotix S.A. (NBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bicara Therapeutics (BCAX) has outperformed Nanobiotix S.A. (NBTX) over the past year, losing 4.1% versus a loss of 16.1%. Nanobiotix S.A. is the larger company by market cap ($1.17 billion vs $1.14 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | NBTX |
|---|---|---|
| Share price | $17.26 | $22.90 |
| Market cap | $1.14B | $1.17B |
| 1-day change | +5.12% | -6.99% |
| YTD return | +2.55% | -0.95% |
| 1-year return | -4.11% | -16.12% |
| 5-year return | — | +78.63% |
| EPS (TTM) | $-3.08 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.99 | $57.14 |
| 52-week low | $13.70 | $14.78 |
| Distance from 52-week high | -44.30% | -59.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +105.68% | +135.28% |
| Average volume | 623.17K | 150.18K |
| Shares outstanding | 66.17M | 50.92M |
| Employees | 103 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCAX has outperformed NBTX by 12.0 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
BCAX vs NBTX FAQ
Which is bigger, Bicara Therapeutics or Nanobiotix S.A.?
Nanobiotix S.A. (NBTX) is larger, with a market capitalization of $1.17B compared with $1.14B for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or NBTX?
BCAX returned -4.11% over the past 12 months, compared with -16.12% for NBTX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Nanobiotix S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.